Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Pancreatic Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Lung Neoplasms 2Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Thrombocythemia, Essential 1Prostatic Neoplasms 1Primary Myelofibrosis 1Polycythemia Vera 1Pdgfra-Associated Chronic Eosinophilic Leukemia 1Neuroendocrine Tumors 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Myeloid, Accelerated Phase 1Kidney Neoplasms 1Gallbladder Neoplasms 1Esophageal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1Breast Neoplasms, Male 1Breast Neoplasms 1Blast Crisis 1Adenocarcinoma, Bronchiolo-Alveolar 1Adenocarcinoma of Lung 1Adenocarcinoma Of Esophagus 1

Interventions

Carboplatin 18Paclitaxel 13Erlotinib Hydrochloride 13Bevacizumab 13Radiotherapy 12Gemcitabine 9Pemetrexed 7Cisplatin 7Gefitinib 6Docetaxel 6Taxes 4Cetuximab 4pegfilgrastim 3Radiosurgery 2Radiation 2Nivolumab 2Neoadjuvant Therapy 2Irinotecan 2Chemotherapy, Adjuvant 2Bortezomib 2pegylated granulocyte colony-stimulating factor 1lentiviral minigene vaccine of COVID-19 coronavirus 1irofulven 1cositecan 1Watchful Waiting 1Vinorelbine 1Video-Assisted Surgery 1Topotecan 1Thalidomide 1Temozolomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Adenocarcinoma, Bronchiolo-Alveolar × 3-aminopyridine-2-carboxaldehyde thiosemicarbazone × Clear all
NCT00077415 2013-05-15

3-AP and Gemcitabine as Second-Line Therapy in Treating Patients With Stage III or Stage IV Recurrent Non-Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 2 Completed
31 enrolled
Thoracic

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡